


## Ciraparantag acetate

Cat. No.:	HY-18660B
CAS No.:	1644388-83-9
Molecular Formula:	C <sub>22</sub> H <sub>48</sub> N <sub>12</sub> O <sub>2</sub> ·xC <sub>2</sub> H <sub>4</sub> O <sub>2</sub>
Target:	Factor Xa
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

In Vitro	H <sub>2</sub> O : 125 mg/mL (Need ultrasonic)
----------	--

### BIOLOGICAL ACTIVITY

Description	Ciraparantag (PER977) acetate is a thrombin and factor Xa inhibitor. Ciraparantag acetate is a broad-spectrum reversal agent for anticoagulants, including low molecular weight heparins, unfractionated heparins, and some direct oral anticoagulants, but not VKAs <sup>[1][2][3][4]</sup> .
-------------	--

### REFERENCES

- [1]. Das A, et al. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015 Sep 15;4:25. [Content Brief]
- [2]. Gomez-Outes A, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2-10. [Content Brief]
- [3]. Hu TY, et al. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016 Feb 17;12:35-44. [Content Brief]
- [4]. Honickel M, et al. The Reversal of Direct Oral Anticoagulants in Animal Models. Shock. 2017 Aug;48(2):144-158. [Content Brief]

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA